Oric Pharmaceuticals, Inc. - Common Stock (ORIC)
9.8600
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 10th, 6:13 AM EDT

The company also announced a $125 million private placement to fund its upcoming Phase 3 trial for ORIC-944 in metastatic prostate cancer.
Via Stocktwits · May 29, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · May 29, 2025

ORIC's Phase 1b trial of ORIC-944 in mCRPC shows PSA responses and strong tolerability, with Phase 3 trials and financing plans underway.
Via Benzinga · May 29, 2025

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · May 29, 2025

Via Benzinga · May 29, 2025

Via Benzinga · May 29, 2025

Via Benzinga · May 29, 2025

Via Benzinga · May 28, 2025

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · May 28, 2025

Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · February 11, 2025

Via Benzinga · January 14, 2025

Via Benzinga · January 10, 2025

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.
Via MarketBeat · November 16, 2024

ORIC stock results show that ORIC Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024

ORIC stock results show that ORIC Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 6, 2024

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.
Via Benzinga · April 19, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · March 21, 2024

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) reported a loss for the fourth quarter on Monday.
Via Benzinga · March 12, 2024

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
Via Benzinga · February 29, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday.
Via Benzinga · February 29, 2024

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers in the United States.
Via Talk Markets · February 7, 2024

Although the bears hate these high potential stocks, other bullish factors suggest the pessimists are due for an unpleasant surprise.
Via InvestorPlace · January 9, 2024

Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly
Via InvestorPlace · December 5, 2023